A low dose of estrogen was as effective as a higher dose in reducing bone turnover and preventing osteoporosis in older women. The study found that women taking 0.25 mg estradiol had no more side effects than those taking a placebo, improving bone health with fewer risks.
The new Diffusion Tensor Magnetic Resonance Imaging (DT-MRI) technology provides detailed maps of brain networks and allows for diagnosis of medical conditions like stroke, as well as assessment of neurological disorders. DT-MRI also holds promise for imaging skeletal muscles, heart, and circulatory system.
Researchers have deciphered the gene sequence of Ralstonia metallidurans, a bacterium that thrives in toxic metals, enabling potential bioremediation applications. The draft genome reveals resistance genes to various heavy metals, paving the way for genetic engineering and monitoring tools.
A study by Cincinnati Children's Hospital Medical Center found that only 21% of mothers of preschoolers feel their children are overweight, highlighting a significant misperception. Mothers with lower education levels were more likely to underestimate childhood obesity and have heavier children.
A new study by UCSF/SFVAMC researchers found that mammography is equally effective in detecting breast cancer in women with and without a family history. The study analyzed data from over 389,000 women and showed that mammography detects nearly 85% of cancers in women aged 50-69, regardless of family history.
A recent study found that young healthy smokers had substantially more lost work days than their non-smoking colleagues. The risk of lost work days was increased by 60% among men who smoked and by 15% among women smokers, with 14% of lost workdays among men and 3% of those among women directly linked to smoking.
A new study by UCSF researchers found that delivering the VEGF growth factor into mice with coronary heart disease prompted the growth of blood vessels in damaged heart tissue without causing side effects. This approach could lead to a treatment strategy for severe coronary heart disease that has been met with setbacks.
Susan Daluge, a North Carolina researcher, has developed a new ant-HIV drug called Ziagen that increases the anti-viral potency of AZT and 3TC. This simplifies treatment for patients who cannot tolerate protease inhibitors due to side effects.
Researchers at Fred Hutchinson Cancer Center have shown promising results with a new antibody treatment, Nuvion, in patients with severe graft versus host disease. The study found that Nuvion was well-tolerated and achieved complete responses in six of nine patients who received a single dose.
Researchers believe that parts of ancient Mars may have resembled a land of lakes, with layered geologic outcrops suggesting sedimentary rock deposited in horizontal layers. The discovery suggests an extremely dynamic environment on early Mars, with water likely playing a key role in shaping the planet's geology.
Researchers found that low-level manganese exposure accelerates Parkinson's symptoms in rats with pre-Parkinsonism, highlighting the need for further studies on toxic substance effects. Manganese toxicity targets different brain regions, exacerbating neurodegenerative diseases like Parkinson's.
Researchers at the University of Pennsylvania have discovered a key protein, VP40, crucial for Ebola's replication cycle. This finding holds promise for developing novel antiviral drugs to stop the spread of the deadly disease.
Researchers Clifford G. Venier and Edward W. Casserly developed a new lubricant called Pennzane® Synthesized Hydrocarbon Fluid X2000 that can withstand extremely low temperatures and prolong satellite life. The lubricant also enhances the longevity of car oils and provides thin coatings for computer disk drives.
A study at the American Society of Hematology Meeting found that patients with acute myeloid leukemia who achieve remission with Mylotarg have prolonged disease-free survival following stem cell transplantation. Researchers also observed fewer complications from bone marrow transplants compared to traditional treatment.
A Phase III study found significant improvements in overall survival, disease-free status, and complete remission rates for patients with aggressive non-Hodgkin's lymphoma treated with MabThera and CHOP chemotherapy. Survival at 1-year was 83% for the rituximab combination therapy group compared to 68% for those receiving CHOP alone.
A new study by Kent State University psychologist Daniel T. Levin found that people's brains tend to classify faces as belonging to a specific race, rather than recognizing individual features. This 'cross-race recognition deficit' affects people of all racial groups and can lead to inaccurate identifications.
Phase II studies indicate that Mylovenge causes regression or stabilization in over 30% of patients with multiple myeloma and amyloidosis, with some benefits lasting up to 18 months. The vaccine stimulates the immune system to recognize and destroy cancer cells.